Showing results (211-220 of 225) with videos related to
Sort By:
Pageof 23
ESMO Real World Data and Digital Oncology|April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine careL Sellmann, D Marschner, U M Martens, et al.ESMO Open|May 6, 2023
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancerT M Reissig, I Tzianopoulos, S-T Liffers, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trialM Schuler, R Berardi, W-T Lim, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2019
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyO Türeci, U Sahin, H Schulze-Bergkamen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyM Schuler, R Herrmann, J L De Greve, et al.Journal of Cancer Research and Clinical Oncology|November 5, 2022
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaM Maßmann, J Treckmann, P Markus, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.ESMO Open|July 17, 2024
Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivityI-A Mavroeidi, J Burghofer, S Kalbourtzis, et al.ESMO Open|January 9, 2024
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter studyJ Keyl, A Bucher, F Jungmann, et al.Pageof 23